WHO Updates Non-severe COVID-19 Treatment Guidance
The World Health Organization updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19.
Tag: Molnupiravir
WHO Updates Non-severe COVID-19 Treatment Guidance
The World Health Organization updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19.
Read More
Merck’s COVID Drug May be Causing the Virus to Mutate
Researchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read More
ACP’s New Guidance Endorses Two COVID-19 Drugs, Advises Against Two
ACP issued four practice points on the pharmacologic and biologic treatment of COVID-19 in the outpatient setting, endorsing two drugs and advising against two others.
Read More
FDA Authorizes Merck Molnupiravir Antiviral COVID Pill
The FDA issued emergency authorization for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults age 18 and older with positive results of direct SARS-CoV-2 viral testing.
Read More